Search
Titanium Dioxide Acetic Acid Citric Acid Sodium Hydroxide Oxalic Acid Ethyl Acetate
Sign in/Join free

insulin glargine

CAS No.: 160337-95-1
Formula: C267H404N72O78S6
Molecular Weight: 6062.89026
Suppliers: All(0) China Suppliers(1) Products(1)
  • Description
  • Basic Info
  • Safety Info
  • Price
What is insulin glargine

**Introduction to Insulin Glargine** Insulin glargine is a long-acting basal insulin analog used to manage type 1 and type 2 diabetes mellitus. Designed to mimic the body's natural basal insulin secretion, it provides a steady and prolonged glucose-lowering effect for up to 24 hours, helping maintain stable blood sugar levels with once-daily dosing. Unlike regular insulin, glargine has a slow, peakless absorption profile, reducing the risk of hypoglycemia. It is typically administered subcutaneously in the evening or morning. Marketed under brand names like Lantus®, Basaglar®, and Toujeo®, insulin glargine is a cornerstone of diabetes therapy, often combined with rapid-acting insulin or oral medications for optimal glycemic control.

Preparation Process: Insulin glargine is prepared via recombinant DNA technology. The human insulin gene is modified to substitute glycine for asparagine at position A21 and add two arginine residues to the B-chain C-terminus. The modified gene is inserted into Escherichia coli or Saccharomyces cerevisiae for expression. The host cells are cultured in a fermentation medium, and the expressed proinsulin analog is harvested. Enzymatic cleavage removes the C-peptide, followed by purification via chromatography (e.g., reverse-phase HPLC). The purified insulin glargine is formulated at pH 4.0 with zinc and m-cresol for stabilization, yielding a clear solution for subcutaneous administration.

Usage Scenarios: Insulin glargine is a long-acting basal insulin analog used to manage blood glucose levels in individuals with type 1 and type 2 diabetes. It provides a steady, peakless insulin release over approximately 24 hours, mimicking the body’s natural basal insulin secretion. Administered once daily via subcutaneous injection, it helps maintain stable fasting glucose levels. Unlike rapid-acting insulins, glargine is not intended to cover mealtime glucose spikes but serves as a background insulin to control hyperglycemia between meals and overnight. It is often combined with short-acting insulins or other antidiabetic medications for optimal glycemic control. Proper dosing and timing are crucial to avoid hypoglycemia.

insulin glargine Basic Info
Chemical Name insulin glargine
Synonyms Lantus;Solostar;Insulin, glycyl(A21)-arginyl(B31,B32)-;Unii-2zm8cx04rz;insulin glargine;Insulin Glargine RS;Insulin glargine CRS;Insulin glargine/C1A;Insulin Glargine EP/USP;insulin glargine USP/EP/BP
CAS No. 160337-95-1
Molecular Formula C267H404N72O78S6
Molecular Weight 6062.89026
PSA -
LogP -
Safely Info
RTECS -
Hazard Class -
Safety Statements -
HS Code 2937120000
WGK Germany -
Packing Group -
RIDADR -
Risk Statements -
Hazard Codes -
Caution Statement P260-P314-P501
Hazard Declaration H373
Symbol GHS08
Signal Word Warning
insulin glargine Price
Here is a rough price range for insulin glargine in the listed countries. Note that prices can vary significantly based on factors like brand, dosage, and healthcare systems. If no specific data is available, "No results" is indicated:

- **United States**: $100–$400 per vial
- **China**: $20–$50 per vial
- **Russia**: $30–$70 per vial
- **Germany**: $40–$80 per vial
- **India**: $10–$30 per vial
- **Japan**: $50–$100 per vial
- **Brazil**: $30–$60 per vial
- **South Korea**: $40–$90 per vial
- **Philippines**: $20–$50 per vial
- **United Kingdom**: $30–$70 per vial (NHS-covered, costs may vary for private purchase)
- **France**: $40–$80 per vial
- **Mexico**: $30–$70 per vial
- **Canada**: $50–$120 per vial
- **South Africa**: $20–$50 per vial
- **Egypt**: $20–$50 per vial
- **Turkey**: $30–$60 per vial
- **Thailand**: $20–$50 per vial
- **Indonesia**: $20–$50 per vial

*Prices are approximate and may vary based on local market conditions, healthcare policies, and availability.*